{"product_id":"pasg-swot-analysis","title":"(PASG) Passage Bio, Inc. SWOT Analysis Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGo Beyond the Preview—Access the Full Reference Sources\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis Passage Bio, Inc. SWOT Analysis helps you quickly assess the company’s strengths, weaknesses, opportunities, and threats in a concise, structured format; the page includes a real preview\/sample of the report so you can judge style and substance before buying. Purchase the full version to download the complete, ready-to-use analysis for research, strategy, or investment work.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eStrengths\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003e6-program rare-disease pipeline\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePassage Bio, Inc. has six named programs—PBGM01, PBFT02, PBKR03, PBML04, PBAL05, and PBCM06—so it has multiple shots on goal in rare central nervous system disorders. That breadth spreads scientific and clinical risk across adjacent indications instead of relying on one asset. In a pipeline this small, six programs is the core strength.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProprietary AAVhu68 and AAV1 capsids\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePassage Bio’s strength is its ownership of 2 proprietary capsids, AAVhu68 and AAV1, used across multiple programs. That platform reuse can lower development friction and create a clearer technical identity than a single-asset story. It also adds IP value, since capsid control can support future pipeline expansion and partnering leverage.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCNS-focused genetic therapy specialization\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePassage Bio’s core strength is its CNS-only genetic therapy focus, which concentrates R\u0026amp;D, CMC, and translational know-how on one of the toughest drug areas. That narrow scope fits rare, high-unmet-need diseases, where even a small approved therapy can matter a lot. It also helps the Company build deep disease expertise instead of spreading capital across broad programs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eUniversity of Pennsylvania collaboration\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePassage Bio, Inc.'s long-running collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program boosts discovery, vector design, and translational know-how. Academic ties like this strengthen scientific credibility in gene therapy and can speed proof-of-concept work from lab to clinic. The Penn partnership also gives Passage Bio, Inc. access to deep academic expertise in AAV science and CNS delivery.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eStronger vector science\u003c\/li\u003e\n\u003cli\u003eBetter translational depth\u003c\/li\u003e\n\u003cli\u003eHigher scientific credibility\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eCatalent development and clinical supply agreement\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePassage Bio, Inc.’s development services and clinical supply agreement with Catalent Maryland, Inc. gives it an outside GMP manufacturing and supply path, which matters for a small gene-therapy company with no internal plant. That setup can speed batch release and help move programs from process development into clinical studies without heavy capital spend.\u003c\/p\u003e\n\u003cp\u003eIt also lowers execution risk on supply planning, since Catalent supports both development work and trial material logistics. For Passage Bio, that kind of partner access is a practical strength when timelines are tight and clinical doses must stay consistent.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eExternal GMP manufacturing support\u003c\/li\u003e\n\u003cli\u003eClinical supply execution backed\u003c\/li\u003e\n\u003cli\u003eLess internal capex needed\u003c\/li\u003e\n\u003cli\u003eHelps advance programs faster\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePassage Bio’s Rare CNS Pipeline Delivers Broad Shots on Goal\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePassage Bio, Inc.'s strength is its six-program rare CNS pipeline, which gives it multiple shots on goal across adjacent indications and lowers single-asset risk. Its two proprietary capsids, AAVhu68 and AAV1, also create platform reuse and IP value. The Penn collaboration and Catalent GMP supply support add scientific depth and execution capacity.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eStrength\u003c\/th\u003e\n\u003cth\u003eData\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePipeline breadth\u003c\/td\u003e\n\u003ctd\u003e6 programs\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProprietary capsids\u003c\/td\u003e\n\u003ctd\u003e2 capsids\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCore partners\u003c\/td\u003e\n\u003ctd\u003ePenn, Catalent\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a clear SWOT framework for analyzing Passage Bio, Inc.’s business strategy\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eEditable Excel File\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a quick, structured SWOT snapshot to simplify Passage Bio, Inc. strategy review and decision-making.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a concise, traceable bibliography of industry reports, clinical data, and regulatory sources to speed due diligence and verify Passage Bio assumptions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eWeaknesses\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFounded in 2017\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eFounded in 2017, Passage Bio is still only about 9 years old in 2026, so its operating record is short versus large biopharma peers. A younger company usually has less proof in commercial launch, FDA interaction, and large-scale manufacturing, which raises execution risk. In gene therapy, where process control and regulatory delivery matter, that limited history can make setbacks more costly.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNo marketed products\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePassage Bio, Inc. remains a development-stage Company with no approved products on the market, so it still has no product revenue to fund operations. That leaves it reliant on outside capital and partner support, which keeps financing risk high and can force dilution or spending cuts. For a gene-therapy biotech, that gap between R\u0026amp;D spend and sales is the core weakness.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConcentration in CNS rare diseases\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePassage Bio, Inc. stays heavily tied to a small set of CNS rare-disease programs, so the story has little diversification. As of fiscal 2025, it still had $0 product revenue, which shows how dependent the company is on a few trial results. That focus can sharpen execution, but one setback can pressure the whole pipeline.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eMultiple programs still in development\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePassage Bio, Inc. still has all six programs in development, and none are commercialized yet, so the company remains exposed to high scientific, clinical, and FDA risk. For a gene-therapy pipeline this early, a single setback can stop a program after years of work and heavy R\u0026amp;D spending.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e6 programs still advancing\u003c\/li\u003e\n\u003cli\u003e0 commercial products today\u003c\/li\u003e\n\u003cli\u003eHigh clinical and regulatory risk\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThat makes success far from assured, because each program must clear safety, efficacy, and manufacturing hurdles before it can generate revenue.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eDependence on external partners\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePassage Bio, Inc. depends on two outside partners, the University of Pennsylvania and Catalent, for core research and manufacturing work. That creates a single-point risk: if either partner slips, timelines, supply, and batch quality can all be hit. It also limits Passage Bio, Inc.'s control over costs and schedule discipline.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2 key partners drive critical work\u003c\/li\u003e\n\u003cli\u003eBottlenecks can delay trials\u003c\/li\u003e\n\u003cli\u003eExternal control can raise costs\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePassage Bio’s Pre-Revenue Pipeline Faces High Execution Risk\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePassage Bio, Inc. is still a young, pre-revenue gene-therapy Company with no approved products, so fiscal 2025 product revenue was $0 and funding risk stays high. Its six-program rare-CNS pipeline is narrow, so one clinical or FDA miss can hurt the whole story. Dependence on the University of Pennsylvania and Catalent also adds schedule and quality risk.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eWeakness\u003c\/th\u003e\n\u003cth\u003eLatest data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eProduct revenue\u003c\/td\u003e\n\u003ctd\u003eFiscal 2025: $0\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCommercial products\u003c\/td\u003e\n\u003ctd\u003e0 approved products\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePipeline \/ partners\u003c\/td\u003e\n\u003ctd\u003e6 programs, 2 key partners\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview Before You Purchase\u003c\/span\u003e\u003cbr\u003ePassage Bio, Inc. Reference Sources\u003c\/h2\u003e\n\u003cp\u003eThis is the actual Passage Bio, Inc. SWOT analysis document you’ll receive upon purchase—no surprises, just professional quality. The preview below is taken directly from the full report; buy now to unlock the complete, editable file with in-depth strengths, weaknesses, opportunities, and threats tailored for investment and strategic use.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Opportunities-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eOpportunities\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLarge unmet need in severe CNS disorders\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePassage Bio focuses on severe CNS disorders with few or no curative options, which can make each successful program more valuable. In rare-disease CNS markets, even small patient pools can draw strong clinical and regulatory interest because the unmet need is so high. For investors, that can lift the payoff from a single approved therapy.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSix-indication platform expansion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePassage Bio, Inc. can reuse one gene-therapy platform across 6 programs: PBGM01, PBFT02, PBKR03, PBML04, PBAL05, and PBCM06. Each readout can cut repeat work in vector design, dosing, and biomarker strategy, so learning from one asset may speed the next. That shared know-how can lift pipeline productivity and improve the odds of moving more than 1 indication forward with less duplication.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Opportunities-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOrphan and rare disease pathways\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePassage Bio, Inc.'s rare CNS targets can fit orphan-drug rules, since U.S. orphan status covers diseases affecting fewer than 200,000 people and can bring 7 years of market exclusivity.\u003c\/p\u003e\n\u003cp\u003eThat matters because rare-disease programs often need smaller trials, so approval can be more feasible than in broad indications.\u003c\/p\u003e\n\u003cp\u003eWith over 300 million people living with rare diseases worldwide, even small patient pools can support meaningful pricing if the therapy shows clear benefit.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePlatform value from capsid and gene delivery science\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePassage Bio, Inc.'s proprietary AAVhu68 and AAV1 capsids could be worth more than one lead program. If the delivery data holds up, the same gene-shuttle tech can support new internal assets and out-licensing, turning a 2-capsid platform into a broader revenue engine.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cp\u003eAAVhu68 and AAV1 may support multiple programs.\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003eValidated delivery science can attract partners.\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003ePlatform value can outlast one asset.\u003c\/p\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePartnership and licensing potential\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePassage Bio, Inc. can use its CNS gene therapy platform and rare-disease programs to strike new collaborations or out-license assets, which could bring in non-dilutive cash and shared development work. Partners may value the company’s focus on hard-to-treat brain disorders, where even one deal can offset R\u0026amp;D burn. This is useful for a small-cap biotech that still needs outside capital.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eOut-license selective CNS programs\u003c\/li\u003e\n\u003cli\u003eAttract rare-disease partners\u003c\/li\u003e\n\u003cli\u003eRaise non-dilutive funding\u003c\/li\u003e\n\u003cli\u003eShare development costs and risk\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePassage Bio’s Hidden Upside: One Platform, Six Shots, More Cash\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePassage Bio’s best upside is platform reuse: 6 programs can share one CNS gene-therapy stack, so each readout can lower follow-on work. Orphan status can also help, since U.S. rules cover diseases under 200,000 people and can give 7 years of exclusivity. Partnering or out-licensing AAVhu68 and AAV1 could add non-dilutive cash.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eOpportunity\u003c\/th\u003e\n\u003cth\u003eData\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePlatform reuse\u003c\/td\u003e\n\u003ctd\u003e6 programs\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOrphan advantage\u003c\/td\u003e\n\u003ctd\u003eUnder 200,000; 7 years\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePartnership upside\u003c\/td\u003e\n\u003ctd\u003e2 capsids: AAVhu68, AAV1\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Threats-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eThreats\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical failure risk\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePassage Bio, Inc. faces high clinical failure risk because gene therapy can break down in preclinical or clinical testing, and CNS studies must prove safety, efficacy, dose, and durability in very small patient groups. In 2025, the company still had no approved product, so a negative readout from even one program could materially cut value and slow financing options.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAAV safety and immunogenicity risk\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAAV safety and immunogenicity remain a real threat for Passage Bio, Inc., especially in systemic and CNS delivery, where immune response and poor tolerability can cap dose. In AAV programs, safety events have already forced dose cuts and program pauses across the field. That can slow timelines, raise cash burn, and weaken the value of each candidate.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Threats-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eManufacturing and supply complexity\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVector production and clinical supply are hard in gene therapy, and Passage Bio, Inc. relies on specialized partners for both. In 2025, Passage Bio, Inc. reported cash, cash equivalents, and marketable securities of $105.6 million, so any delay can burn capital fast. One stalled batch or partner issue can slow trials and raise CMC costs. Scale-up is still a wide industry problem.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eIntense gene therapy competition\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePassage Bio, Inc. faces heavy gene therapy competition, with many biotech and large pharma groups chasing CNS and rare-disease programs, so its data and delivery platform must stand out fast. In a market where only a few gene therapies have won broad approval, rivals with deeper cash can spend more on trials, manufacturing, and BD. That pressure can raise partner costs and make top scientific hires harder to secure.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMore rivals, higher bar.\u003c\/li\u003e\n\u003cli\u003eCapital efficiency matters more.\u003c\/li\u003e\n\u003cli\u003ePartners and talent get scarcer.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eCapital market and regulatory uncertainty\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePassage Bio, Inc. faces capital market risk because gene-therapy work burns cash before any revenue arrives, so tight funding can slow trials and push readouts out. In a tougher biotech market, higher financing costs and weaker investor appetite can force smaller raises or dilutive terms. Regulatory rules for gene therapy can also change, adding review delays and more compliance work.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCapital access can slow trial progress.\u003c\/li\u003e\n\u003cli\u003eDilution risk rises in weak markets.\u003c\/li\u003e\n\u003cli\u003eGene therapy rules can shift fast.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePassage Bio Faces High 2025 Trial Risk and Cash Pressure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePassage Bio, Inc. still faces high trial-failure risk in 2025 because its CNS gene therapy programs must prove safety, dose, durability, and efficacy in small studies. It had no approved product, and cash, cash equivalents, and marketable securities were $105.6 million, so any setback can hit value fast. AAV safety, supply, and competition can also delay data and raise burn.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eThreat\u003c\/th\u003e\n\u003cth\u003e2025 Data\u003c\/th\u003e\n\u003cth\u003eWhy it matters\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinical failure\u003c\/td\u003e\n\u003ctd\u003eNo approved product\u003c\/td\u003e\n\u003ctd\u003eOne bad readout can cut value\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLiquidity\u003c\/td\u003e\n\u003ctd\u003e$105.6 million cash\u003c\/td\u003e\n\u003ctd\u003eDelays can force more dilution\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57234837864713,"sku":"pasg-swot-analysis","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/pasg-swot-analysis.webp?v=1785728153","url":"https:\/\/dcfanalyst.com\/products\/pasg-swot-analysis","provider":"DCF Analyst","version":"1.0","type":"link"}